Search Result

Results for "

Gemcitabine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Akt (3) Aldose Reductase (1) Apoptosis (18) Aurora Kinase (1) Autophagy (9) Biochemical Assay Reagents (1) c-Fms (1) CDK (1) Checkpoint Kinase (Chk) (6) DNA/RNA Synthesis (9) Drug Metabolite (3) Drug-Linker Conjugates for ADC (1) Endogenous Metabolite (3) Enterovirus (1) ERK (1) FGFR (1) FLT3 (1) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) Influenza Virus (1) Integrin (1) Isotope-Labeled Compounds (1) MDM-2/p53 (3) MMP (1) mTOR (2) NF-κB (1) Nucleoside Antimetabolite/Analog (11) PI3K (1) PKC (1) RET (1) Ribosomal S6 Kinase (RSK) (1) SARS-CoV (1) Sirtuin (2) Src (1) VEGFR (1) Wnt (1)
By Research Areas:	Cancer (43) Endocrinology (2) Infection (2) Inflammation/Immunology (3) Neurological Disease (1)

By Targets:

ADC Linker (1)

Akt (3)

Aldose Reductase (1)

Apoptosis (18)

Aurora Kinase (1)

Autophagy (9)

Biochemical Assay Reagents (1)

c-Fms (1)

CDK (1)

Checkpoint Kinase (Chk) (6)

DNA/RNA Synthesis (9)

Drug Metabolite (3)

Drug-Linker Conjugates for ADC (1)

Endogenous Metabolite (3)

Enterovirus (1)

ERK (1)

FGFR (1)

FLT3 (1)

HDAC (3)

HIF/HIF Prolyl-Hydroxylase (1)

Influenza Virus (1)

Integrin (1)

Isotope-Labeled Compounds (1)

MDM-2/p53 (3)

MMP (1)

mTOR (2)

NF-κB (1)

Nucleoside Antimetabolite/Analog (11)

PI3K (1)

PKC (1)

RET (1)

Ribosomal S6 Kinase (RSK) (1)

SARS-CoV (1)

Sirtuin (2)

Src (1)

VEGFR (1)

Wnt (1)

By Research Areas:

Cancer (43)

Endocrinology (2)

Infection (2)

Inflammation/Immunology (3)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17026

*Gemcitabine* Maximum Cited Publications 151 Publications Verification LY 188011	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis	Cancer
Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-108932

Gemcitabine monophosphate Gemcitabine 5′-phosphate	Apoptosis	Cancer
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .

HY-130812

Gemcitabine-O-Si(di-iso)-O-Mc	Drug-Linker Conjugates for ADC	Cancer
Gemcitabine-O-Si(di-iso)-O-Mc is a agent-linker conjugate for ADC with potent antitumor activity by using Gemcitabine (a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent; HY-17026), linked via the ADC linker .

HY-13538

Gemcitabine elaidate 4 Publications Verification CP-4126; CO-101; Gemcitabine 5'-elaidate	Nucleoside Antimetabolite/Analog Autophagy Apoptosis	Cancer
Gemcitabine elaidate (CP-4126) is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate exhibits anti-tumor activity .

HY-13538A

Gemcitabine elaidate hydrochloride 4 Publications Verification CP-4126 hydrochloride; CO-101 hydrochloride; Gemcitabine 5'-elaidate hydrochloride	Nucleoside Antimetabolite/Analog Autophagy Apoptosis	Cancer
Gemcitabine elaidate (CP-4126) hydrochloride is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated. Gemcitabine elaidate hydrochloride exhibits anti-tumor activity .

HY-17026E

Gemcitabine triphosphate trisodium dFdCTP trisodium	Endogenous Metabolite	Cancer
Gemcitabine triphosphate (trisodium) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .

HY-108932A

Gemcitabine monophosphate disodium Gemcitabine 5′-phosphate disodium	Apoptosis	Cancer
Gemcitabine monophosphate (Gemcitabine 5′-phosphate) is one of the active intermediates of Gemcitabine (HY-17026). Gemcitabine monophosphate has a synergistic anti-cancer effect and can be delivered by formulating it into nanoparticles .

HY-17026R

Gemcitabine (Standard)	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis	Cancer
Gemcitabine (Standard) is the analytical standard of Gemcitabine. This product is intended for research and analytical applications. Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-17026A

Gemcitabine triphosphate dFdCTP	Drug Metabolite Endogenous Metabolite	Cancer
Gemcitabine triphosphate (dFdCTP) is one of the two nucleoside metabolites of Gemcitabine (HY-17026) in cells. The other is active diphosphate (dFdDTP). Gemcitabine triphosphate can be used as a standard in radio-labeled probe imaging studies, to identify tumors sensitive to Gemcitabine, and to evaluate Gemcitabine uptake and retention by cells .

HY-B0003R

Gemcitabine hydrochloride (Standard) LY 188011 hydrochloride (Standard)	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Autophagy Apoptosis	Cancer
Gemcitabine (hydrochloride) (Standard) is the analytical standard of Gemcitabine (hydrochloride). This product is intended for research and analytical applications. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-B0003

Gemcitabine hydrochloride Maximum Cited Publications 151 Publications Verification LY 188011 hydrochloride	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Autophagy Apoptosis	Cancer
Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-B0003S

Gemcitabine-13C,15N2 hydrochloride LY 188011-¹³C,¹⁵N₂ hydrochloride	Apoptosis Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy	Cancer
Gemcitabine- ¹³C, ¹⁵N₂ (hydrochloride) is the ¹³C and ¹⁵N labeled Gemcitabine hydrochloride[1]. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[2][3].

HY-B0003A

*1'-epi Gemcitabine* hydrochloride** 1'-epi LY 188011 hydrochloride	Apoptosis	Cancer
1'-epi Gemcitabine hydrochloride is the isomer of Gemcitabine hydrochloride (HY-B0003), and can be used as an experimental control. Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis .

HY-B0003AS

*(2S)-Gemcitabine-13C,15N2 hydrochloride*	Isotope-Labeled Compounds	Others
(2S)-Gemcitabine- ¹³C, ¹⁵N₂ (hydrochloride) is the ¹³C and ¹⁵N labeled (2S)-Gemcitabine hydrochloride[1].

HY-138253

2′,2′-Difluorodeoxyuridine dFdU; 2',2'-Difluoro-2'-deoxyuridine	Drug Metabolite	Cancer
2′,2′-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2′,2′-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro .

HY-13672

LY2334737 1 Publications Verification	Nucleoside Antimetabolite/Analog Enterovirus	Infection Cancer
LY2334737 is an nucleoside analog and is an orally active proagent of Gemcitabine. LY2334737 exhibits inhibitory activity against enterovirus A71 (EV-A71) infection. LY2334737 has antiviral and anticancer effects .

HY-138253R

2′,2′-Difluorodeoxyuridine (Standard)	Drug Metabolite	Cancer
2′,2′-Difluorodeoxyuridine (Standard) is the analytical standard of 2′,2′-Difluorodeoxyuridine. This product is intended for research and analytical applications. 2′,2′-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2′,2′-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro .

HY-160818

MC3138	Sirtuin	Cancer
MC3138 is a selective SIRT5 activator. MC3138 has antitumor activity on human PDAC cells, with IC₅₀ values of 25.4-236.9 μM. MC3138 combined with Gemcitabine (HY-17026) significantly inhibits tumor growth in mice .

HY-P5021

Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) c(RGDfE)	Biochemical Assay Reagents	Cancer
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) (c(RGDfE)) is a cyclic RGD peptide that serves as a conjugated multifunctional nanodrug delivery system to target Gemcitabine to pancreatic cancer cells. Cyclo(Arg-Gly-Asp-(D-Phe)-Glu) can be used in cancer research .

HY-10032

PF 477736 5 Publications Verification PF 00477736	Checkpoint Kinase (Chk) VEGFR Src c-Fms Aurora Kinase FGFR FLT3 RET CDK	Cancer
PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a K_i of 0.49 nM, it is also a Chk2 inhibitor, with a K_i of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3, and Ret (IC₅₀=8 (K_i), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo .

HY-113314

AFMK	Endogenous Metabolite	Cancer
AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pK_a of AFMK at physiological pH is 8.7. Antioxidant capacity . AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway .

HY-15883

GNE-900	Checkpoint Kinase (Chk) Apoptosis	Cancer
GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC₅₀s of 0.0011, 1.5 µM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. gemcitabine (HY-17026) and GNE-900 administration shows anti-tumor activity .

HY-149050

Viral polymerase-IN-1 hydrochloride	Influenza Virus SARS-CoV	Infection
Viral polymerase-IN-1 hydrochloride, a Gemcitabine (HY-17026) derivative, potently inhibits influenza A and B viruses infection with IC₉₀ values of 11.4-15.9 μM. Viral polymerase-IN-1 hydrochloride is active against SARS-CoV-2 infection. Viral polymerase-IN-1 hydrochloride suppresses influenza virus infection by affecting viral RNA replication/transcription in cells .

HY-146540

GEM-5	HIF/HIF Prolyl-Hydroxylase Apoptosis MDM-2/p53	Cancer
GEM-5 is a gemcitabine-based conjugate containing a HIF-1α inhibitor (YC-1) (IC₅₀=30 nM). GEM-5 can significantly down-regulate the expression of HIF-1α and up-regulate the expression of tumor suppressor p53. GEM-5 induces the apoptosis of A2780 cells and inhibits tumor growth .

HY-154842

S-Gem	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis	Cancer
S-Gem is a TrxR-dependent prodrug of Gemcitabine (HY-17026) and selectively activated by TrxR. S-Gem shows less cytotoxicity compared to Gemcitabine .

HY-100709

ZPCK SL-01	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Autophagy Apoptosis	Cancer
ZPCK is an oral active proagent of gemcitabine that was designed for improved oral bioavailability .

HY-100885

Acelarin 1 Publications Verification NUC-1031	DNA/RNA Synthesis	Cancer
Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.

HY-159577

Nic-15	PI3K mTOR Akt	Cancer
Nic-15 (compound 4n) is an anti-constrictive agent used to antagonize the hypovascularity of pancreatic tumors. The hypovascularity allows cancer cells to adapt to the nutrient-deficient tumor microenvironment and develop drug resistance. Nic-15 can regulate the PI3K/Akt/mTOR pathway and alleviate ER stress induced by Gemcitabine (HY-17026). Nic-15 can significantly inhibit the migration and colony formation of MIA PaCa-2 and PANC-1 pancreatic cancer cells. The combination of Nic-15 and Gemcitabine can effectively solve the problem of pancreatic tumor resistance. In an in vivo xenograft model, Nic-15 can significantly enhance the efficacy of Gemcitabine .

HY-130818

N-(5-Hydroxypentyl)maleimide	ADC Linker	Cancer
N-(5-Hydroxypentyl)maleimide is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as Gemcitabine-O-Si(di-iso)-O-Mc (HY-130812) ) .

HY-123597

NSC 109555 DDUG; NCI C04808	Others	Cancer
NSC 109555 is an ATP-competitive inhibitor of checkpoint kinase 2 (Chk2; IC₅₀=200 nM in a cell-free kinase assay). It is selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK with IC₅₀ values of 210, 6,000, 7,400, and 7,100 nM, respectively. NSC 109555 inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC₅₀=240 nM). It inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro.2 NSC 109555 (1,250 nM) potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of reactive oxygen species (ROS) in MIA PaCa-2 cells.

HY-115528

FF-10502	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis	Cancer
FF-10502, a structural analog of Gemcitabine, is a pyrimidine nucleoside antimetabolite. FF-10502 inhibits DNA polymerase α and β. FF-10502 shows beneficial anticancer activity via a mechanism of action on dormant cells .

HY-145441

GEM–IB	Others	Cancer
GEM–IB is the conjugate of gemcitabine (GEM)-5'-phosphate with ibandronate (IB). GEM–IB as a single agent or in combination with Docetaxel (DTX) demonstrates reduced tumor burden, preservation of the bone architecture, and improved the survival in a murine model of osteosarcoma (OS) .

HY-16138

Ivaltinostat CG-200745	HDAC MDM-2/p53 Apoptosis	Cancer
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects .

HY-16138A

Ivaltinostat formic CG-200745 formic	HDAC MDM-2/p53 Apoptosis	Inflammation/Immunology Endocrinology Cancer
Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects .

HY-145314

TC113	Integrin	Cancer
TC113 is a c(RGDyK)-Based conjugate of Gemcitabine (GEM). TC113 could be internalized by A549 cells through integrin α_vβ₃. TC113 shows potent antiproliferative properties against WM266.4 and A549 cells .

HY-163323

AKR1C3-IN-12	Aldose Reductase	Cancer
AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC₅₀ of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer .

HY-161383

CHK1-IN-9	Checkpoint Kinase (Chk)	Cancer
CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC₅₀ value of 0.55 nM. CHK1-IN-9 can enhance the effect of DNA-damaging drugs on tumor cells. CHK1-IN-9 has synergistic anticancer effects with Gemcitabine (HY-17026) .

HY-103367

CHK1-IN-7	Checkpoint Kinase (Chk)	Cancer
CHK1-IN-7 (Compound 10c) is a potent human CHK1 inhibitor. CHK1-IN-7 shows no single agent effect, potentiates the antiproliferative effect of Gemcitabine HY-17026 in both prostate and breast cancer cell lines. CHK1-IN-7 can be used for the research of cancer .

HY-124731

PD-321852	Checkpoint Kinase (Chk)	Cancer
PD-321852 is a Chk1 inhibitor, with Chk1 of 5 nM. PD-321852 can be used in anti-cancer research .

HY-15882

GNE-783	Others	Cancer
GNE-783 is a selective CHK1 inhibitor that enhances the activity of gemcitabine. GNE-783 improves the efficacy of anti-metabolite DNA damage drugs by inactivating S-phase and G2-phase cell cycle checkpoints following DNA damage. GNE-783 selectively enhances the chemical synergy of certain drugs in different tumor types, for example, enhancing the activity of temozolomide only in melanoma cell lines .

HY-100195

SAR-020106 1 Publications Verification	Checkpoint Kinase (Chk)	Cancer
SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC₅₀ of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents .

HY-156027

SIRT6-IN-3	Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK	Neurological Disease Inflammation/Immunology Endocrinology Cancer
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research .

HY-P99667

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-N3387

Licoricidin	Apoptosis NF-κB Akt MMP	Inflammation/Immunology Cancer
Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC₅₀=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .

HY-169006

Evo312	Apoptosis PKC	Cancer
Evo312 is a dose-dependent inhibitor of protein kinase CβⅠ (PKCβⅠ) (IC₅₀ is 117.34 nM). Evo312 induces PANC-GR (acquired gemcitabine-resistant PC cells) cell cycle arrest and apoptosis by inhibiting PKCβ1 protein expression. Evo312 has antiproliferative effects in pancreatic cancer cells PANC-1 and PANC-GR cells with IC₅₀ of 0.08 μM and 0.07 μM, and in human normal pancreatic ductal epithelial cells HPDE6-c7 with IC₅₀ of 2.95 μM. Evo312 exhibits antitumor activity in a PANC-GR cell transplantation mouse model .

Cat. No.	Product Name	Target	Research Area